Scientists have uncovered a new way to curb autoimmunity and stimulate the body to fight cancer. The method uses a previously unknown druggable pathway to manipulate immune cells.
The discovery concerns a molecule called tetrahydrobiopterin (BH4), which is already well-known to those who study the biology of the brain and nervous system.
T cells are white blood cells that seek out and attack potentially harmful pathogens, such as viruses, bacteria, and rogue cells, including those that can trigger cancer.
The leaders of the study are researchers at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna and others at the Boston Children’s Hospital in Massachusetts. The journal Nature recently published the findings.
“One fascinating feature of our discovery is that a system that is actually known in neurobiology for decades can play such a key role in T cell biology,” says co-senior author Josef M. Penninger, the scientific and founding director of IMBA.
He explains that the finding “links two completely different systems in our body” and that it “was truly amazing to find such a critical new player in T cell biology.”
What is particularly interesting, he adds, is that the discovery concerns the control of T cell growth, as opposed to the cells’ activation.
The finding should lead to a wide variety of medical uses, ranging “from controlling autoimmune diseases, asthma, and allergies to having a new way to trigger anticancer immunity,” Penninger concludes.
Harnessing the body’s own healing mechanisms to fight disease is a fast-growing field in medical research.
Two scientists won the 2018 Nobel Prize in Physiology or Medicine after developing an approach to cancer therapy that stimulates the immune system’s inherent ability to destroy tumor cells.
Such discoveries are driving a revolution in the way that we treat cancer, a disease that affects millions of people worldwide and has a significant impact on society.
The National Cancer Institute estimate that in 2018, doctors will diagnose 1,735,350 new cases of cancer and that 609,640 people will die from the disease in the United States.
Diseases can also result from an overactive or misdirected immune system. There are
The American Autoimmune Related Diseases Association, however, say that the NIH figures only take into account 24 autoimmune diseases and that the actual figure is more likely to be about 50 million.
The body uses BH4 to make serotonin and dopamine, two hormones that send signals between cells in the brain and the nervous system.
The authors of the new study showed that the molecule is also crucial for T cell biology. They demonstrated that reducing cell production of BH4 “severely” limits the “proliferation of mature mouse and human T cells.”
It seems that T cells need BH4 to help them regulate iron and produce energy. This is consistent with findings from much older research, which linked iron deficiency to problems with the immune system.
In mouse models of cancer, the team found that increasing BH4 caused more T cells to grow and tumors to shrink. It appears that BH4 does this by overcoming a molecule called kynurenine that normally suppresses T cell growth in tumors.
Co-senior author Clifford J. Woolf, director of the F.M. Kirby Neurobiology Center at Boston Children’s Hospital, marvels that “a molecule recognized as essential for many functions in neurobiology is now identified as key for completely novel therapies.”
Describing the effects of altering the amount of BH4, Woolf explains, “When we dial it down, we block T cell proliferation in autoimmune diseases or asthma. When we dial it up, we can trigger T cells to grow and attack tumor cells, even under adverse conditions.”
The researchers tested some BH4 blockers on mouse models of allergies and autoimmune diseases. The drugs “calmed” auto-aggressive T cells, stopped allergic inflammation, and prevented T cells from causing autoimmune attacks in the gut and brain.
They hope to test a drug based on the approach in humans soon.
“The beauty of the approach is that instead of targeting a single cytokine or class of T cells, we halt proliferation in all disease-related T cells, and this could translate into activity across multiple diverse clinical conditions.”
Clifford J. Woolf